Clinical Research Trials Archive – Closed Trials

This is our archive of closed clinical trials, which means that they are no longer accepting new participants or have been concluded. Once a research facility has chosen to close the study, it is sorted into the GPS archive by indication. If you are interested in enrolling in a clinical trial, then please browse our list of active clinical studies.

Zip code

Condition


Search Radius:25 Miles
  • 5
  • 10
  • 15
  • 20
  • 25
  • 30
  • 40
  • 50
  • 100
  • 500
  • All

We've found
4,191
archived clinical trials in
Constipation

26 Week Efficacy and Safety Trial for Patients With Chronic Idiopathic Constipation
A Double-blind, Randomised, Placebo-controlled, Phase 3 Trial in Patients With Chronic Idiopathic Constipation to Demonstrate the Efficacy and Safety of Elobixibat 5 mg and 10 mg for 26 Weeks
Status: Enrolling
Updated:  9/22/2015
Northwest Gastroenterology Associates
mi
from
Bellevue, WA
26 Week Efficacy and Safety Trial for Patients With Chronic Idiopathic Constipation
A Double-blind, Randomised, Placebo-controlled, Phase 3 Trial in Patients With Chronic Idiopathic Constipation to Demonstrate the Efficacy and Safety of Elobixibat 5 mg and 10 mg for 26 Weeks
Status: Enrolling
Updated: 9/22/2015
Northwest Gastroenterology Associates
mi
from
Bellevue, WA
Click here to add this to my saved trials
26 Week Efficacy and Safety Trial for Patients With Chronic Idiopathic Constipation
A Double-blind, Randomised, Placebo-controlled, Phase 3 Trial in Patients With Chronic Idiopathic Constipation to Demonstrate the Efficacy and Safety of Elobixibat 5 mg and 10 mg for 26 Weeks
Status: Enrolling
Updated:  9/22/2015
Cliniques Universitaires Saint-Luc
mi
from
Brussels,
26 Week Efficacy and Safety Trial for Patients With Chronic Idiopathic Constipation
A Double-blind, Randomised, Placebo-controlled, Phase 3 Trial in Patients With Chronic Idiopathic Constipation to Demonstrate the Efficacy and Safety of Elobixibat 5 mg and 10 mg for 26 Weeks
Status: Enrolling
Updated: 9/22/2015
Cliniques Universitaires Saint-Luc
mi
from
Brussels,
Click here to add this to my saved trials
Efficacy and Safety Trial of Elobixibat in Patients With Chronic Idiopathic Constipation
A Double-blind, Randomised, Placebo-controlled, Phase 3 Trial in Patients With Chronic Idiopathic Constipation to Demonstrate the Efficacy and Safety of Elobixibat 5 mg and 10 mg for 12 Weeks Followed by a 4-week Withdrawal Period
Status: Enrolling
Updated:  9/22/2015
Birmingham Gastroenterology Associates P.C.
mi
from
Birmingham, AL
Efficacy and Safety Trial of Elobixibat in Patients With Chronic Idiopathic Constipation
A Double-blind, Randomised, Placebo-controlled, Phase 3 Trial in Patients With Chronic Idiopathic Constipation to Demonstrate the Efficacy and Safety of Elobixibat 5 mg and 10 mg for 12 Weeks Followed by a 4-week Withdrawal Period
Status: Enrolling
Updated: 9/22/2015
Birmingham Gastroenterology Associates P.C.
mi
from
Birmingham, AL
Click here to add this to my saved trials
Efficacy and Safety Trial of Elobixibat in Patients With Chronic Idiopathic Constipation
A Double-blind, Randomised, Placebo-controlled, Phase 3 Trial in Patients With Chronic Idiopathic Constipation to Demonstrate the Efficacy and Safety of Elobixibat 5 mg and 10 mg for 12 Weeks Followed by a 4-week Withdrawal Period
Status: Enrolling
Updated:  9/22/2015
Genova Clinical Research
mi
from
Tucson, AZ
Efficacy and Safety Trial of Elobixibat in Patients With Chronic Idiopathic Constipation
A Double-blind, Randomised, Placebo-controlled, Phase 3 Trial in Patients With Chronic Idiopathic Constipation to Demonstrate the Efficacy and Safety of Elobixibat 5 mg and 10 mg for 12 Weeks Followed by a 4-week Withdrawal Period
Status: Enrolling
Updated: 9/22/2015
Genova Clinical Research
mi
from
Tucson, AZ
Click here to add this to my saved trials
Efficacy and Safety Trial of Elobixibat in Patients With Chronic Idiopathic Constipation
A Double-blind, Randomised, Placebo-controlled, Phase 3 Trial in Patients With Chronic Idiopathic Constipation to Demonstrate the Efficacy and Safety of Elobixibat 5 mg and 10 mg for 12 Weeks Followed by a 4-week Withdrawal Period
Status: Enrolling
Updated:  9/22/2015
Preferred Research Partners, Inc.
mi
from
Little Rock, AR
Efficacy and Safety Trial of Elobixibat in Patients With Chronic Idiopathic Constipation
A Double-blind, Randomised, Placebo-controlled, Phase 3 Trial in Patients With Chronic Idiopathic Constipation to Demonstrate the Efficacy and Safety of Elobixibat 5 mg and 10 mg for 12 Weeks Followed by a 4-week Withdrawal Period
Status: Enrolling
Updated: 9/22/2015
Preferred Research Partners, Inc.
mi
from
Little Rock, AR
Click here to add this to my saved trials
Efficacy and Safety Trial of Elobixibat in Patients With Chronic Idiopathic Constipation
A Double-blind, Randomised, Placebo-controlled, Phase 3 Trial in Patients With Chronic Idiopathic Constipation to Demonstrate the Efficacy and Safety of Elobixibat 5 mg and 10 mg for 12 Weeks Followed by a 4-week Withdrawal Period
Status: Enrolling
Updated:  9/22/2015
Arkansas Gastroenterology
mi
from
North Little Rock, AR
Efficacy and Safety Trial of Elobixibat in Patients With Chronic Idiopathic Constipation
A Double-blind, Randomised, Placebo-controlled, Phase 3 Trial in Patients With Chronic Idiopathic Constipation to Demonstrate the Efficacy and Safety of Elobixibat 5 mg and 10 mg for 12 Weeks Followed by a 4-week Withdrawal Period
Status: Enrolling
Updated: 9/22/2015
Arkansas Gastroenterology
mi
from
North Little Rock, AR
Click here to add this to my saved trials
Efficacy and Safety Trial of Elobixibat in Patients With Chronic Idiopathic Constipation
A Double-blind, Randomised, Placebo-controlled, Phase 3 Trial in Patients With Chronic Idiopathic Constipation to Demonstrate the Efficacy and Safety of Elobixibat 5 mg and 10 mg for 12 Weeks Followed by a 4-week Withdrawal Period
Status: Enrolling
Updated:  9/22/2015
West Gastroenterology Associates
mi
from
Los Angeles, CA
Efficacy and Safety Trial of Elobixibat in Patients With Chronic Idiopathic Constipation
A Double-blind, Randomised, Placebo-controlled, Phase 3 Trial in Patients With Chronic Idiopathic Constipation to Demonstrate the Efficacy and Safety of Elobixibat 5 mg and 10 mg for 12 Weeks Followed by a 4-week Withdrawal Period
Status: Enrolling
Updated: 9/22/2015
West Gastroenterology Associates
mi
from
Los Angeles, CA
Click here to add this to my saved trials
Efficacy and Safety Trial of Elobixibat in Patients With Chronic Idiopathic Constipation
A Double-blind, Randomised, Placebo-controlled, Phase 3 Trial in Patients With Chronic Idiopathic Constipation to Demonstrate the Efficacy and Safety of Elobixibat 5 mg and 10 mg for 12 Weeks Followed by a 4-week Withdrawal Period
Status: Enrolling
Updated:  9/22/2015
David Geffen School of Medicine at University of California Los Angeles
mi
from
Los Angeles, CA
Efficacy and Safety Trial of Elobixibat in Patients With Chronic Idiopathic Constipation
A Double-blind, Randomised, Placebo-controlled, Phase 3 Trial in Patients With Chronic Idiopathic Constipation to Demonstrate the Efficacy and Safety of Elobixibat 5 mg and 10 mg for 12 Weeks Followed by a 4-week Withdrawal Period
Status: Enrolling
Updated: 9/22/2015
David Geffen School of Medicine at University of California Los Angeles
mi
from
Los Angeles, CA
Click here to add this to my saved trials
Efficacy and Safety Trial of Elobixibat in Patients With Chronic Idiopathic Constipation
A Double-blind, Randomised, Placebo-controlled, Phase 3 Trial in Patients With Chronic Idiopathic Constipation to Demonstrate the Efficacy and Safety of Elobixibat 5 mg and 10 mg for 12 Weeks Followed by a 4-week Withdrawal Period
Status: Enrolling
Updated:  9/22/2015
Sacramento Research Medical Group
mi
from
Sacramento, CA
Efficacy and Safety Trial of Elobixibat in Patients With Chronic Idiopathic Constipation
A Double-blind, Randomised, Placebo-controlled, Phase 3 Trial in Patients With Chronic Idiopathic Constipation to Demonstrate the Efficacy and Safety of Elobixibat 5 mg and 10 mg for 12 Weeks Followed by a 4-week Withdrawal Period
Status: Enrolling
Updated: 9/22/2015
Sacramento Research Medical Group
mi
from
Sacramento, CA
Click here to add this to my saved trials
Efficacy and Safety Trial of Elobixibat in Patients With Chronic Idiopathic Constipation
A Double-blind, Randomised, Placebo-controlled, Phase 3 Trial in Patients With Chronic Idiopathic Constipation to Demonstrate the Efficacy and Safety of Elobixibat 5 mg and 10 mg for 12 Weeks Followed by a 4-week Withdrawal Period
Status: Enrolling
Updated:  9/22/2015
Precision Research Institute, LLC
mi
from
San Diego, CA
Efficacy and Safety Trial of Elobixibat in Patients With Chronic Idiopathic Constipation
A Double-blind, Randomised, Placebo-controlled, Phase 3 Trial in Patients With Chronic Idiopathic Constipation to Demonstrate the Efficacy and Safety of Elobixibat 5 mg and 10 mg for 12 Weeks Followed by a 4-week Withdrawal Period
Status: Enrolling
Updated: 9/22/2015
Precision Research Institute, LLC
mi
from
San Diego, CA
Click here to add this to my saved trials
Efficacy and Safety Trial of Elobixibat in Patients With Chronic Idiopathic Constipation
A Double-blind, Randomised, Placebo-controlled, Phase 3 Trial in Patients With Chronic Idiopathic Constipation to Demonstrate the Efficacy and Safety of Elobixibat 5 mg and 10 mg for 12 Weeks Followed by a 4-week Withdrawal Period
Status: Enrolling
Updated:  9/22/2015
Gastroenterology Associates of Fairfield County
mi
from
Bridgeport, CT
Efficacy and Safety Trial of Elobixibat in Patients With Chronic Idiopathic Constipation
A Double-blind, Randomised, Placebo-controlled, Phase 3 Trial in Patients With Chronic Idiopathic Constipation to Demonstrate the Efficacy and Safety of Elobixibat 5 mg and 10 mg for 12 Weeks Followed by a 4-week Withdrawal Period
Status: Enrolling
Updated: 9/22/2015
Gastroenterology Associates of Fairfield County
mi
from
Bridgeport, CT
Click here to add this to my saved trials
Efficacy and Safety Trial of Elobixibat in Patients With Chronic Idiopathic Constipation
A Double-blind, Randomised, Placebo-controlled, Phase 3 Trial in Patients With Chronic Idiopathic Constipation to Demonstrate the Efficacy and Safety of Elobixibat 5 mg and 10 mg for 12 Weeks Followed by a 4-week Withdrawal Period
Status: Enrolling
Updated:  9/22/2015
Zasa Clinical Research
mi
from
Boynton Beach, FL
Efficacy and Safety Trial of Elobixibat in Patients With Chronic Idiopathic Constipation
A Double-blind, Randomised, Placebo-controlled, Phase 3 Trial in Patients With Chronic Idiopathic Constipation to Demonstrate the Efficacy and Safety of Elobixibat 5 mg and 10 mg for 12 Weeks Followed by a 4-week Withdrawal Period
Status: Enrolling
Updated: 9/22/2015
Zasa Clinical Research
mi
from
Boynton Beach, FL
Click here to add this to my saved trials
Efficacy and Safety Trial of Elobixibat in Patients With Chronic Idiopathic Constipation
A Double-blind, Randomised, Placebo-controlled, Phase 3 Trial in Patients With Chronic Idiopathic Constipation to Demonstrate the Efficacy and Safety of Elobixibat 5 mg and 10 mg for 12 Weeks Followed by a 4-week Withdrawal Period
Status: Enrolling
Updated:  9/22/2015
Meridien Research
mi
from
Bradenton, FL
Efficacy and Safety Trial of Elobixibat in Patients With Chronic Idiopathic Constipation
A Double-blind, Randomised, Placebo-controlled, Phase 3 Trial in Patients With Chronic Idiopathic Constipation to Demonstrate the Efficacy and Safety of Elobixibat 5 mg and 10 mg for 12 Weeks Followed by a 4-week Withdrawal Period
Status: Enrolling
Updated: 9/22/2015
Meridien Research
mi
from
Bradenton, FL
Click here to add this to my saved trials
Efficacy and Safety Trial of Elobixibat in Patients With Chronic Idiopathic Constipation
A Double-blind, Randomised, Placebo-controlled, Phase 3 Trial in Patients With Chronic Idiopathic Constipation to Demonstrate the Efficacy and Safety of Elobixibat 5 mg and 10 mg for 12 Weeks Followed by a 4-week Withdrawal Period
Status: Enrolling
Updated:  9/22/2015
Sanitas Research
mi
from
Coral Gables, FL
Efficacy and Safety Trial of Elobixibat in Patients With Chronic Idiopathic Constipation
A Double-blind, Randomised, Placebo-controlled, Phase 3 Trial in Patients With Chronic Idiopathic Constipation to Demonstrate the Efficacy and Safety of Elobixibat 5 mg and 10 mg for 12 Weeks Followed by a 4-week Withdrawal Period
Status: Enrolling
Updated: 9/22/2015
Sanitas Research
mi
from
Coral Gables, FL
Click here to add this to my saved trials
Efficacy and Safety Trial of Elobixibat in Patients With Chronic Idiopathic Constipation
A Double-blind, Randomised, Placebo-controlled, Phase 3 Trial in Patients With Chronic Idiopathic Constipation to Demonstrate the Efficacy and Safety of Elobixibat 5 mg and 10 mg for 12 Weeks Followed by a 4-week Withdrawal Period
Status: Enrolling
Updated:  9/22/2015
Lake Internal Medicine Associates
mi
from
Eustis, FL
Efficacy and Safety Trial of Elobixibat in Patients With Chronic Idiopathic Constipation
A Double-blind, Randomised, Placebo-controlled, Phase 3 Trial in Patients With Chronic Idiopathic Constipation to Demonstrate the Efficacy and Safety of Elobixibat 5 mg and 10 mg for 12 Weeks Followed by a 4-week Withdrawal Period
Status: Enrolling
Updated: 9/22/2015
Lake Internal Medicine Associates
mi
from
Eustis, FL
Click here to add this to my saved trials
Efficacy and Safety Trial of Elobixibat in Patients With Chronic Idiopathic Constipation
A Double-blind, Randomised, Placebo-controlled, Phase 3 Trial in Patients With Chronic Idiopathic Constipation to Demonstrate the Efficacy and Safety of Elobixibat 5 mg and 10 mg for 12 Weeks Followed by a 4-week Withdrawal Period
Status: Enrolling
Updated:  9/22/2015
Health Care Family Rehab Corp.
mi
from
Hialeah, FL
Efficacy and Safety Trial of Elobixibat in Patients With Chronic Idiopathic Constipation
A Double-blind, Randomised, Placebo-controlled, Phase 3 Trial in Patients With Chronic Idiopathic Constipation to Demonstrate the Efficacy and Safety of Elobixibat 5 mg and 10 mg for 12 Weeks Followed by a 4-week Withdrawal Period
Status: Enrolling
Updated: 9/22/2015
Health Care Family Rehab Corp.
mi
from
Hialeah, FL
Click here to add this to my saved trials
Efficacy and Safety Trial of Elobixibat in Patients With Chronic Idiopathic Constipation
A Double-blind, Randomised, Placebo-controlled, Phase 3 Trial in Patients With Chronic Idiopathic Constipation to Demonstrate the Efficacy and Safety of Elobixibat 5 mg and 10 mg for 12 Weeks Followed by a 4-week Withdrawal Period
Status: Enrolling
Updated:  9/22/2015
Southeast Clinical Research, Llc
mi
from
Jacksonville, FL
Efficacy and Safety Trial of Elobixibat in Patients With Chronic Idiopathic Constipation
A Double-blind, Randomised, Placebo-controlled, Phase 3 Trial in Patients With Chronic Idiopathic Constipation to Demonstrate the Efficacy and Safety of Elobixibat 5 mg and 10 mg for 12 Weeks Followed by a 4-week Withdrawal Period
Status: Enrolling
Updated: 9/22/2015
Southeast Clinical Research, Llc
mi
from
Jacksonville, FL
Click here to add this to my saved trials
Efficacy and Safety Trial of Elobixibat in Patients With Chronic Idiopathic Constipation
A Double-blind, Randomised, Placebo-controlled, Phase 3 Trial in Patients With Chronic Idiopathic Constipation to Demonstrate the Efficacy and Safety of Elobixibat 5 mg and 10 mg for 12 Weeks Followed by a 4-week Withdrawal Period
Status: Enrolling
Updated:  9/22/2015
Health Awareness
mi
from
Jupiter, FL
Efficacy and Safety Trial of Elobixibat in Patients With Chronic Idiopathic Constipation
A Double-blind, Randomised, Placebo-controlled, Phase 3 Trial in Patients With Chronic Idiopathic Constipation to Demonstrate the Efficacy and Safety of Elobixibat 5 mg and 10 mg for 12 Weeks Followed by a 4-week Withdrawal Period
Status: Enrolling
Updated: 9/22/2015
Health Awareness
mi
from
Jupiter, FL
Click here to add this to my saved trials
Efficacy and Safety Trial of Elobixibat in Patients With Chronic Idiopathic Constipation
A Double-blind, Randomised, Placebo-controlled, Phase 3 Trial in Patients With Chronic Idiopathic Constipation to Demonstrate the Efficacy and Safety of Elobixibat 5 mg and 10 mg for 12 Weeks Followed by a 4-week Withdrawal Period
Status: Enrolling
Updated:  9/22/2015
Mount Vernon Clinical Research
mi
from
Atlanta, GA
Efficacy and Safety Trial of Elobixibat in Patients With Chronic Idiopathic Constipation
A Double-blind, Randomised, Placebo-controlled, Phase 3 Trial in Patients With Chronic Idiopathic Constipation to Demonstrate the Efficacy and Safety of Elobixibat 5 mg and 10 mg for 12 Weeks Followed by a 4-week Withdrawal Period
Status: Enrolling
Updated: 9/22/2015
Mount Vernon Clinical Research
mi
from
Atlanta, GA
Click here to add this to my saved trials
Efficacy and Safety Trial of Elobixibat in Patients With Chronic Idiopathic Constipation
A Double-blind, Randomised, Placebo-controlled, Phase 3 Trial in Patients With Chronic Idiopathic Constipation to Demonstrate the Efficacy and Safety of Elobixibat 5 mg and 10 mg for 12 Weeks Followed by a 4-week Withdrawal Period
Status: Enrolling
Updated:  9/22/2015
Southeast Regional Research Group
mi
from
Columbus, GA
Efficacy and Safety Trial of Elobixibat in Patients With Chronic Idiopathic Constipation
A Double-blind, Randomised, Placebo-controlled, Phase 3 Trial in Patients With Chronic Idiopathic Constipation to Demonstrate the Efficacy and Safety of Elobixibat 5 mg and 10 mg for 12 Weeks Followed by a 4-week Withdrawal Period
Status: Enrolling
Updated: 9/22/2015
Southeast Regional Research Group
mi
from
Columbus, GA
Click here to add this to my saved trials
Efficacy and Safety Trial of Elobixibat in Patients With Chronic Idiopathic Constipation
A Double-blind, Randomised, Placebo-controlled, Phase 3 Trial in Patients With Chronic Idiopathic Constipation to Demonstrate the Efficacy and Safety of Elobixibat 5 mg and 10 mg for 12 Weeks Followed by a 4-week Withdrawal Period
Status: Enrolling
Updated:  9/22/2015
Premier Healthcare Research, LLC
mi
from
Evanston, IL
Efficacy and Safety Trial of Elobixibat in Patients With Chronic Idiopathic Constipation
A Double-blind, Randomised, Placebo-controlled, Phase 3 Trial in Patients With Chronic Idiopathic Constipation to Demonstrate the Efficacy and Safety of Elobixibat 5 mg and 10 mg for 12 Weeks Followed by a 4-week Withdrawal Period
Status: Enrolling
Updated: 9/22/2015
Premier Healthcare Research, LLC
mi
from
Evanston, IL
Click here to add this to my saved trials
Efficacy and Safety Trial of Elobixibat in Patients With Chronic Idiopathic Constipation
A Double-blind, Randomised, Placebo-controlled, Phase 3 Trial in Patients With Chronic Idiopathic Constipation to Demonstrate the Efficacy and Safety of Elobixibat 5 mg and 10 mg for 12 Weeks Followed by a 4-week Withdrawal Period
Status: Enrolling
Updated:  9/22/2015
Rockford Gastroenterology Associates, Ltd.
mi
from
Rockford, IL
Efficacy and Safety Trial of Elobixibat in Patients With Chronic Idiopathic Constipation
A Double-blind, Randomised, Placebo-controlled, Phase 3 Trial in Patients With Chronic Idiopathic Constipation to Demonstrate the Efficacy and Safety of Elobixibat 5 mg and 10 mg for 12 Weeks Followed by a 4-week Withdrawal Period
Status: Enrolling
Updated: 9/22/2015
Rockford Gastroenterology Associates, Ltd.
mi
from
Rockford, IL
Click here to add this to my saved trials
Efficacy and Safety Trial of Elobixibat in Patients With Chronic Idiopathic Constipation
A Double-blind, Randomised, Placebo-controlled, Phase 3 Trial in Patients With Chronic Idiopathic Constipation to Demonstrate the Efficacy and Safety of Elobixibat 5 mg and 10 mg for 12 Weeks Followed by a 4-week Withdrawal Period
Status: Enrolling
Updated:  9/22/2015
Heartland Research Associates, LLC
mi
from
Augusta, KA
Efficacy and Safety Trial of Elobixibat in Patients With Chronic Idiopathic Constipation
A Double-blind, Randomised, Placebo-controlled, Phase 3 Trial in Patients With Chronic Idiopathic Constipation to Demonstrate the Efficacy and Safety of Elobixibat 5 mg and 10 mg for 12 Weeks Followed by a 4-week Withdrawal Period
Status: Enrolling
Updated: 9/22/2015
Heartland Research Associates, LLC
mi
from
Augusta, KA
Click here to add this to my saved trials
Efficacy and Safety Trial of Elobixibat in Patients With Chronic Idiopathic Constipation
A Double-blind, Randomised, Placebo-controlled, Phase 3 Trial in Patients With Chronic Idiopathic Constipation to Demonstrate the Efficacy and Safety of Elobixibat 5 mg and 10 mg for 12 Weeks Followed by a 4-week Withdrawal Period
Status: Enrolling
Updated:  9/22/2015
Heartland Research Associates, LLC
mi
from
Wichita, KA
Efficacy and Safety Trial of Elobixibat in Patients With Chronic Idiopathic Constipation
A Double-blind, Randomised, Placebo-controlled, Phase 3 Trial in Patients With Chronic Idiopathic Constipation to Demonstrate the Efficacy and Safety of Elobixibat 5 mg and 10 mg for 12 Weeks Followed by a 4-week Withdrawal Period
Status: Enrolling
Updated: 9/22/2015
Heartland Research Associates, LLC
mi
from
Wichita, KA
Click here to add this to my saved trials
Efficacy and Safety Trial of Elobixibat in Patients With Chronic Idiopathic Constipation
A Double-blind, Randomised, Placebo-controlled, Phase 3 Trial in Patients With Chronic Idiopathic Constipation to Demonstrate the Efficacy and Safety of Elobixibat 5 mg and 10 mg for 12 Weeks Followed by a 4-week Withdrawal Period
Status: Enrolling
Updated:  9/22/2015
Professional Research Network of Kansas, LLC
mi
from
Witchita, KA
Efficacy and Safety Trial of Elobixibat in Patients With Chronic Idiopathic Constipation
A Double-blind, Randomised, Placebo-controlled, Phase 3 Trial in Patients With Chronic Idiopathic Constipation to Demonstrate the Efficacy and Safety of Elobixibat 5 mg and 10 mg for 12 Weeks Followed by a 4-week Withdrawal Period
Status: Enrolling
Updated: 9/22/2015
Professional Research Network of Kansas, LLC
mi
from
Witchita, KA
Click here to add this to my saved trials
Efficacy and Safety Trial of Elobixibat in Patients With Chronic Idiopathic Constipation
A Double-blind, Randomised, Placebo-controlled, Phase 3 Trial in Patients With Chronic Idiopathic Constipation to Demonstrate the Efficacy and Safety of Elobixibat 5 mg and 10 mg for 12 Weeks Followed by a 4-week Withdrawal Period
Status: Enrolling
Updated:  9/22/2015
Louisiana Research Center, LLC
mi
from
Shreveport, LA
Efficacy and Safety Trial of Elobixibat in Patients With Chronic Idiopathic Constipation
A Double-blind, Randomised, Placebo-controlled, Phase 3 Trial in Patients With Chronic Idiopathic Constipation to Demonstrate the Efficacy and Safety of Elobixibat 5 mg and 10 mg for 12 Weeks Followed by a 4-week Withdrawal Period
Status: Enrolling
Updated: 9/22/2015
Louisiana Research Center, LLC
mi
from
Shreveport, LA
Click here to add this to my saved trials
Efficacy and Safety Trial of Elobixibat in Patients With Chronic Idiopathic Constipation
A Double-blind, Randomised, Placebo-controlled, Phase 3 Trial in Patients With Chronic Idiopathic Constipation to Demonstrate the Efficacy and Safety of Elobixibat 5 mg and 10 mg for 12 Weeks Followed by a 4-week Withdrawal Period
Status: Enrolling
Updated:  9/22/2015
Beacon Clinical Research, LLC
mi
from
Brockton, MA
Efficacy and Safety Trial of Elobixibat in Patients With Chronic Idiopathic Constipation
A Double-blind, Randomised, Placebo-controlled, Phase 3 Trial in Patients With Chronic Idiopathic Constipation to Demonstrate the Efficacy and Safety of Elobixibat 5 mg and 10 mg for 12 Weeks Followed by a 4-week Withdrawal Period
Status: Enrolling
Updated: 9/22/2015
Beacon Clinical Research, LLC
mi
from
Brockton, MA
Click here to add this to my saved trials
Efficacy and Safety Trial of Elobixibat in Patients With Chronic Idiopathic Constipation
A Double-blind, Randomised, Placebo-controlled, Phase 3 Trial in Patients With Chronic Idiopathic Constipation to Demonstrate the Efficacy and Safety of Elobixibat 5 mg and 10 mg for 12 Weeks Followed by a 4-week Withdrawal Period
Status: Enrolling
Updated:  9/22/2015
Quality Clinical Research, Inc.
mi
from
Omaha, NE
Efficacy and Safety Trial of Elobixibat in Patients With Chronic Idiopathic Constipation
A Double-blind, Randomised, Placebo-controlled, Phase 3 Trial in Patients With Chronic Idiopathic Constipation to Demonstrate the Efficacy and Safety of Elobixibat 5 mg and 10 mg for 12 Weeks Followed by a 4-week Withdrawal Period
Status: Enrolling
Updated: 9/22/2015
Quality Clinical Research, Inc.
mi
from
Omaha, NE
Click here to add this to my saved trials
Efficacy and Safety Trial of Elobixibat in Patients With Chronic Idiopathic Constipation
A Double-blind, Randomised, Placebo-controlled, Phase 3 Trial in Patients With Chronic Idiopathic Constipation to Demonstrate the Efficacy and Safety of Elobixibat 5 mg and 10 mg for 12 Weeks Followed by a 4-week Withdrawal Period
Status: Enrolling
Updated:  9/22/2015
Long Island Gastrointestinal Research Group
mi
from
Great Neck, NY
Efficacy and Safety Trial of Elobixibat in Patients With Chronic Idiopathic Constipation
A Double-blind, Randomised, Placebo-controlled, Phase 3 Trial in Patients With Chronic Idiopathic Constipation to Demonstrate the Efficacy and Safety of Elobixibat 5 mg and 10 mg for 12 Weeks Followed by a 4-week Withdrawal Period
Status: Enrolling
Updated: 9/22/2015
Long Island Gastrointestinal Research Group
mi
from
Great Neck, NY
Click here to add this to my saved trials
Efficacy and Safety Trial of Elobixibat in Patients With Chronic Idiopathic Constipation
A Double-blind, Randomised, Placebo-controlled, Phase 3 Trial in Patients With Chronic Idiopathic Constipation to Demonstrate the Efficacy and Safety of Elobixibat 5 mg and 10 mg for 12 Weeks Followed by a 4-week Withdrawal Period
Status: Enrolling
Updated:  9/22/2015
Carolina Digestive Health Associates
mi
from
Charlotte, NC
Efficacy and Safety Trial of Elobixibat in Patients With Chronic Idiopathic Constipation
A Double-blind, Randomised, Placebo-controlled, Phase 3 Trial in Patients With Chronic Idiopathic Constipation to Demonstrate the Efficacy and Safety of Elobixibat 5 mg and 10 mg for 12 Weeks Followed by a 4-week Withdrawal Period
Status: Enrolling
Updated: 9/22/2015
Carolina Digestive Health Associates
mi
from
Charlotte, NC
Click here to add this to my saved trials
Efficacy and Safety Trial of Elobixibat in Patients With Chronic Idiopathic Constipation
A Double-blind, Randomised, Placebo-controlled, Phase 3 Trial in Patients With Chronic Idiopathic Constipation to Demonstrate the Efficacy and Safety of Elobixibat 5 mg and 10 mg for 12 Weeks Followed by a 4-week Withdrawal Period
Status: Enrolling
Updated:  9/22/2015
Carolina Digestive Health Associates, PA
mi
from
Concord, NC
Efficacy and Safety Trial of Elobixibat in Patients With Chronic Idiopathic Constipation
A Double-blind, Randomised, Placebo-controlled, Phase 3 Trial in Patients With Chronic Idiopathic Constipation to Demonstrate the Efficacy and Safety of Elobixibat 5 mg and 10 mg for 12 Weeks Followed by a 4-week Withdrawal Period
Status: Enrolling
Updated: 9/22/2015
Carolina Digestive Health Associates, PA
mi
from
Concord, NC
Click here to add this to my saved trials
Efficacy and Safety Trial of Elobixibat in Patients With Chronic Idiopathic Constipation
A Double-blind, Randomised, Placebo-controlled, Phase 3 Trial in Patients With Chronic Idiopathic Constipation to Demonstrate the Efficacy and Safety of Elobixibat 5 mg and 10 mg for 12 Weeks Followed by a 4-week Withdrawal Period
Status: Enrolling
Updated:  9/22/2015
Pharmquest
mi
from
Greensboro, NC
Efficacy and Safety Trial of Elobixibat in Patients With Chronic Idiopathic Constipation
A Double-blind, Randomised, Placebo-controlled, Phase 3 Trial in Patients With Chronic Idiopathic Constipation to Demonstrate the Efficacy and Safety of Elobixibat 5 mg and 10 mg for 12 Weeks Followed by a 4-week Withdrawal Period
Status: Enrolling
Updated: 9/22/2015
Pharmquest
mi
from
Greensboro, NC
Click here to add this to my saved trials
Efficacy and Safety Trial of Elobixibat in Patients With Chronic Idiopathic Constipation
A Double-blind, Randomised, Placebo-controlled, Phase 3 Trial in Patients With Chronic Idiopathic Constipation to Demonstrate the Efficacy and Safety of Elobixibat 5 mg and 10 mg for 12 Weeks Followed by a 4-week Withdrawal Period
Status: Enrolling
Updated:  9/22/2015
Peters Medical Research
mi
from
HIgh Point, NC
Efficacy and Safety Trial of Elobixibat in Patients With Chronic Idiopathic Constipation
A Double-blind, Randomised, Placebo-controlled, Phase 3 Trial in Patients With Chronic Idiopathic Constipation to Demonstrate the Efficacy and Safety of Elobixibat 5 mg and 10 mg for 12 Weeks Followed by a 4-week Withdrawal Period
Status: Enrolling
Updated: 9/22/2015
Peters Medical Research
mi
from
HIgh Point, NC
Click here to add this to my saved trials
Efficacy and Safety Trial of Elobixibat in Patients With Chronic Idiopathic Constipation
A Double-blind, Randomised, Placebo-controlled, Phase 3 Trial in Patients With Chronic Idiopathic Constipation to Demonstrate the Efficacy and Safety of Elobixibat 5 mg and 10 mg for 12 Weeks Followed by a 4-week Withdrawal Period
Status: Enrolling
Updated:  9/22/2015
Wake Research Associates, LLC
mi
from
Raleigh, NC
Efficacy and Safety Trial of Elobixibat in Patients With Chronic Idiopathic Constipation
A Double-blind, Randomised, Placebo-controlled, Phase 3 Trial in Patients With Chronic Idiopathic Constipation to Demonstrate the Efficacy and Safety of Elobixibat 5 mg and 10 mg for 12 Weeks Followed by a 4-week Withdrawal Period
Status: Enrolling
Updated: 9/22/2015
Wake Research Associates, LLC
mi
from
Raleigh, NC
Click here to add this to my saved trials
Efficacy and Safety Trial of Elobixibat in Patients With Chronic Idiopathic Constipation
A Double-blind, Randomised, Placebo-controlled, Phase 3 Trial in Patients With Chronic Idiopathic Constipation to Demonstrate the Efficacy and Safety of Elobixibat 5 mg and 10 mg for 12 Weeks Followed by a 4-week Withdrawal Period
Status: Enrolling
Updated:  9/22/2015
Hometown Urgent Care and Occupational Health
mi
from
Columbus, OH
Efficacy and Safety Trial of Elobixibat in Patients With Chronic Idiopathic Constipation
A Double-blind, Randomised, Placebo-controlled, Phase 3 Trial in Patients With Chronic Idiopathic Constipation to Demonstrate the Efficacy and Safety of Elobixibat 5 mg and 10 mg for 12 Weeks Followed by a 4-week Withdrawal Period
Status: Enrolling
Updated: 9/22/2015
Hometown Urgent Care and Occupational Health
mi
from
Columbus, OH
Click here to add this to my saved trials
Efficacy and Safety Trial of Elobixibat in Patients With Chronic Idiopathic Constipation
A Double-blind, Randomised, Placebo-controlled, Phase 3 Trial in Patients With Chronic Idiopathic Constipation to Demonstrate the Efficacy and Safety of Elobixibat 5 mg and 10 mg for 12 Weeks Followed by a 4-week Withdrawal Period
Status: Enrolling
Updated:  9/22/2015
Hometown Urgent Care and Occupational Health
mi
from
Dayton, OH
Efficacy and Safety Trial of Elobixibat in Patients With Chronic Idiopathic Constipation
A Double-blind, Randomised, Placebo-controlled, Phase 3 Trial in Patients With Chronic Idiopathic Constipation to Demonstrate the Efficacy and Safety of Elobixibat 5 mg and 10 mg for 12 Weeks Followed by a 4-week Withdrawal Period
Status: Enrolling
Updated: 9/22/2015
Hometown Urgent Care and Occupational Health
mi
from
Dayton, OH
Click here to add this to my saved trials
Efficacy and Safety Trial of Elobixibat in Patients With Chronic Idiopathic Constipation
A Double-blind, Randomised, Placebo-controlled, Phase 3 Trial in Patients With Chronic Idiopathic Constipation to Demonstrate the Efficacy and Safety of Elobixibat 5 mg and 10 mg for 12 Weeks Followed by a 4-week Withdrawal Period
Status: Enrolling
Updated:  9/22/2015
Family Practice Center Of Wadsworth, Inc.
mi
from
Wadsworth, OH
Efficacy and Safety Trial of Elobixibat in Patients With Chronic Idiopathic Constipation
A Double-blind, Randomised, Placebo-controlled, Phase 3 Trial in Patients With Chronic Idiopathic Constipation to Demonstrate the Efficacy and Safety of Elobixibat 5 mg and 10 mg for 12 Weeks Followed by a 4-week Withdrawal Period
Status: Enrolling
Updated: 9/22/2015
Family Practice Center Of Wadsworth, Inc.
mi
from
Wadsworth, OH
Click here to add this to my saved trials
Efficacy and Safety Trial of Elobixibat in Patients With Chronic Idiopathic Constipation
A Double-blind, Randomised, Placebo-controlled, Phase 3 Trial in Patients With Chronic Idiopathic Constipation to Demonstrate the Efficacy and Safety of Elobixibat 5 mg and 10 mg for 12 Weeks Followed by a 4-week Withdrawal Period
Status: Enrolling
Updated:  9/22/2015
Clinical Research Associates, LLC
mi
from
Oklahoma City, OK
Efficacy and Safety Trial of Elobixibat in Patients With Chronic Idiopathic Constipation
A Double-blind, Randomised, Placebo-controlled, Phase 3 Trial in Patients With Chronic Idiopathic Constipation to Demonstrate the Efficacy and Safety of Elobixibat 5 mg and 10 mg for 12 Weeks Followed by a 4-week Withdrawal Period
Status: Enrolling
Updated: 9/22/2015
Clinical Research Associates, LLC
mi
from
Oklahoma City, OK
Click here to add this to my saved trials
Efficacy and Safety Trial of Elobixibat in Patients With Chronic Idiopathic Constipation
A Double-blind, Randomised, Placebo-controlled, Phase 3 Trial in Patients With Chronic Idiopathic Constipation to Demonstrate the Efficacy and Safety of Elobixibat 5 mg and 10 mg for 12 Weeks Followed by a 4-week Withdrawal Period
Status: Enrolling
Updated:  9/22/2015
Sunstone Medical Research, LLC
mi
from
Medford, OR
Efficacy and Safety Trial of Elobixibat in Patients With Chronic Idiopathic Constipation
A Double-blind, Randomised, Placebo-controlled, Phase 3 Trial in Patients With Chronic Idiopathic Constipation to Demonstrate the Efficacy and Safety of Elobixibat 5 mg and 10 mg for 12 Weeks Followed by a 4-week Withdrawal Period
Status: Enrolling
Updated: 9/22/2015
Sunstone Medical Research, LLC
mi
from
Medford, OR
Click here to add this to my saved trials
Efficacy and Safety Trial of Elobixibat in Patients With Chronic Idiopathic Constipation
A Double-blind, Randomised, Placebo-controlled, Phase 3 Trial in Patients With Chronic Idiopathic Constipation to Demonstrate the Efficacy and Safety of Elobixibat 5 mg and 10 mg for 12 Weeks Followed by a 4-week Withdrawal Period
Status: Enrolling
Updated:  9/22/2015
Family Medical Associates
mi
from
Levittown, PA
Efficacy and Safety Trial of Elobixibat in Patients With Chronic Idiopathic Constipation
A Double-blind, Randomised, Placebo-controlled, Phase 3 Trial in Patients With Chronic Idiopathic Constipation to Demonstrate the Efficacy and Safety of Elobixibat 5 mg and 10 mg for 12 Weeks Followed by a 4-week Withdrawal Period
Status: Enrolling
Updated: 9/22/2015
Family Medical Associates
mi
from
Levittown, PA
Click here to add this to my saved trials
Efficacy and Safety Trial of Elobixibat in Patients With Chronic Idiopathic Constipation
A Double-blind, Randomised, Placebo-controlled, Phase 3 Trial in Patients With Chronic Idiopathic Constipation to Demonstrate the Efficacy and Safety of Elobixibat 5 mg and 10 mg for 12 Weeks Followed by a 4-week Withdrawal Period
Status: Enrolling
Updated:  9/22/2015
Anderson Gastroenterology Associates, LLC
mi
from
Anderson, SC
Efficacy and Safety Trial of Elobixibat in Patients With Chronic Idiopathic Constipation
A Double-blind, Randomised, Placebo-controlled, Phase 3 Trial in Patients With Chronic Idiopathic Constipation to Demonstrate the Efficacy and Safety of Elobixibat 5 mg and 10 mg for 12 Weeks Followed by a 4-week Withdrawal Period
Status: Enrolling
Updated: 9/22/2015
Anderson Gastroenterology Associates, LLC
mi
from
Anderson, SC
Click here to add this to my saved trials
Efficacy and Safety Trial of Elobixibat in Patients With Chronic Idiopathic Constipation
A Double-blind, Randomised, Placebo-controlled, Phase 3 Trial in Patients With Chronic Idiopathic Constipation to Demonstrate the Efficacy and Safety of Elobixibat 5 mg and 10 mg for 12 Weeks Followed by a 4-week Withdrawal Period
Status: Enrolling
Updated:  9/22/2015
Palmetto Clinical Research
mi
from
Summerville, SC
Efficacy and Safety Trial of Elobixibat in Patients With Chronic Idiopathic Constipation
A Double-blind, Randomised, Placebo-controlled, Phase 3 Trial in Patients With Chronic Idiopathic Constipation to Demonstrate the Efficacy and Safety of Elobixibat 5 mg and 10 mg for 12 Weeks Followed by a 4-week Withdrawal Period
Status: Enrolling
Updated: 9/22/2015
Palmetto Clinical Research
mi
from
Summerville, SC
Click here to add this to my saved trials
Efficacy and Safety Trial of Elobixibat in Patients With Chronic Idiopathic Constipation
A Double-blind, Randomised, Placebo-controlled, Phase 3 Trial in Patients With Chronic Idiopathic Constipation to Demonstrate the Efficacy and Safety of Elobixibat 5 mg and 10 mg for 12 Weeks Followed by a 4-week Withdrawal Period
Status: Enrolling
Updated:  9/22/2015
Associates in Gastroenterology
mi
from
Hermitage, TN
Efficacy and Safety Trial of Elobixibat in Patients With Chronic Idiopathic Constipation
A Double-blind, Randomised, Placebo-controlled, Phase 3 Trial in Patients With Chronic Idiopathic Constipation to Demonstrate the Efficacy and Safety of Elobixibat 5 mg and 10 mg for 12 Weeks Followed by a 4-week Withdrawal Period
Status: Enrolling
Updated: 9/22/2015
Associates in Gastroenterology
mi
from
Hermitage, TN
Click here to add this to my saved trials
Efficacy and Safety Trial of Elobixibat in Patients With Chronic Idiopathic Constipation
A Double-blind, Randomised, Placebo-controlled, Phase 3 Trial in Patients With Chronic Idiopathic Constipation to Demonstrate the Efficacy and Safety of Elobixibat 5 mg and 10 mg for 12 Weeks Followed by a 4-week Withdrawal Period
Status: Enrolling
Updated:  9/22/2015
HCCA Clinical Research Solutions
mi
from
Jackson, TN
Efficacy and Safety Trial of Elobixibat in Patients With Chronic Idiopathic Constipation
A Double-blind, Randomised, Placebo-controlled, Phase 3 Trial in Patients With Chronic Idiopathic Constipation to Demonstrate the Efficacy and Safety of Elobixibat 5 mg and 10 mg for 12 Weeks Followed by a 4-week Withdrawal Period
Status: Enrolling
Updated: 9/22/2015
HCCA Clinical Research Solutions
mi
from
Jackson, TN
Click here to add this to my saved trials
Efficacy and Safety Trial of Elobixibat in Patients With Chronic Idiopathic Constipation
A Double-blind, Randomised, Placebo-controlled, Phase 3 Trial in Patients With Chronic Idiopathic Constipation to Demonstrate the Efficacy and Safety of Elobixibat 5 mg and 10 mg for 12 Weeks Followed by a 4-week Withdrawal Period
Status: Enrolling
Updated:  9/22/2015
New Phase Research & Development
mi
from
Knoxville, TN
Efficacy and Safety Trial of Elobixibat in Patients With Chronic Idiopathic Constipation
A Double-blind, Randomised, Placebo-controlled, Phase 3 Trial in Patients With Chronic Idiopathic Constipation to Demonstrate the Efficacy and Safety of Elobixibat 5 mg and 10 mg for 12 Weeks Followed by a 4-week Withdrawal Period
Status: Enrolling
Updated: 9/22/2015
New Phase Research & Development
mi
from
Knoxville, TN
Click here to add this to my saved trials
Efficacy and Safety Trial of Elobixibat in Patients With Chronic Idiopathic Constipation
A Double-blind, Randomised, Placebo-controlled, Phase 3 Trial in Patients With Chronic Idiopathic Constipation to Demonstrate the Efficacy and Safety of Elobixibat 5 mg and 10 mg for 12 Weeks Followed by a 4-week Withdrawal Period
Status: Enrolling
Updated:  9/22/2015
Research Across America
mi
from
Katy, TX
Efficacy and Safety Trial of Elobixibat in Patients With Chronic Idiopathic Constipation
A Double-blind, Randomised, Placebo-controlled, Phase 3 Trial in Patients With Chronic Idiopathic Constipation to Demonstrate the Efficacy and Safety of Elobixibat 5 mg and 10 mg for 12 Weeks Followed by a 4-week Withdrawal Period
Status: Enrolling
Updated: 9/22/2015
Research Across America
mi
from
Katy, TX
Click here to add this to my saved trials
Efficacy and Safety Trial of Elobixibat in Patients With Chronic Idiopathic Constipation
A Double-blind, Randomised, Placebo-controlled, Phase 3 Trial in Patients With Chronic Idiopathic Constipation to Demonstrate the Efficacy and Safety of Elobixibat 5 mg and 10 mg for 12 Weeks Followed by a 4-week Withdrawal Period
Status: Enrolling
Updated:  9/22/2015
Gastroenterology Associates of Tidewater
mi
from
Chesapeake, VA
Efficacy and Safety Trial of Elobixibat in Patients With Chronic Idiopathic Constipation
A Double-blind, Randomised, Placebo-controlled, Phase 3 Trial in Patients With Chronic Idiopathic Constipation to Demonstrate the Efficacy and Safety of Elobixibat 5 mg and 10 mg for 12 Weeks Followed by a 4-week Withdrawal Period
Status: Enrolling
Updated: 9/22/2015
Gastroenterology Associates of Tidewater
mi
from
Chesapeake, VA
Click here to add this to my saved trials
Efficacy and Safety Trial of Elobixibat in Patients With Chronic Idiopathic Constipation
A Double-blind, Randomised, Placebo-controlled, Phase 3 Trial in Patients With Chronic Idiopathic Constipation to Demonstrate the Efficacy and Safety of Elobixibat 5 mg and 10 mg for 12 Weeks Followed by a 4-week Withdrawal Period
Status: Enrolling
Updated:  9/22/2015
Fundacao IMEPEM - Universidade Federal de Juiz de Fora
mi
from
Juiz de Fora,
Efficacy and Safety Trial of Elobixibat in Patients With Chronic Idiopathic Constipation
A Double-blind, Randomised, Placebo-controlled, Phase 3 Trial in Patients With Chronic Idiopathic Constipation to Demonstrate the Efficacy and Safety of Elobixibat 5 mg and 10 mg for 12 Weeks Followed by a 4-week Withdrawal Period
Status: Enrolling
Updated: 9/22/2015
Fundacao IMEPEM - Universidade Federal de Juiz de Fora
mi
from
Juiz de Fora,
Click here to add this to my saved trials
Predictors of Constipation in Healthy Children
Predictors of Constipation in Healthy Children
Status: Enrolling
Updated:  10/1/2015
Group Health Pediatrics- Capital
mi
from
Madison, WI
Predictors of Constipation in Healthy Children
Predictors of Constipation in Healthy Children
Status: Enrolling
Updated: 10/1/2015
Group Health Pediatrics- Capital
mi
from
Madison, WI
Click here to add this to my saved trials
Predictors of Constipation in Healthy Children
Predictors of Constipation in Healthy Children
Status: Enrolling
Updated:  10/1/2015
UW East Pediatric Clinic
mi
from
Madison, WI
Predictors of Constipation in Healthy Children
Predictors of Constipation in Healthy Children
Status: Enrolling
Updated: 10/1/2015
UW East Pediatric Clinic
mi
from
Madison, WI
Click here to add this to my saved trials